Tirzepatide Dosage Chart for a 10 mg/mL Compounded Vial

When your compounded tirzepatide vial is labeled 10 mg/mL, every milliliter of liquid contains 10 milligrams of medication. Using a standard U-100 insulin syringe (100 units = 1 mL), the conversions are:

2.5 mg = 25 units 5.0 mg = 50 units 7.5 mg = 75 units 10.0 mg = 100 units 12.5 mg = 125 units (exceeds a single 1 mL syringe) 15.0 mg = 150 units (exceeds a single 1 mL syringe)

All values come from the formula: units = (dose in mg / 10 mg per mL) x 100. At 10 mg/mL, the shortcut is: multiply your milligram dose by 10 to get units.

Important: The 10 mg dose (100 units) fills an entire 1.0 mL syringe. Doses of 12.5 mg and 15 mg require more than 1 mL and cannot be drawn in a single U-100 syringe at this concentration. Patients on those doses need a higher-concentration vial.

Tirzepatide treatment follows a gradual escalation. Here is the context for each dose on the chart.

2.5 mg (25 units) is the initiation dose for all patients. It is held for four weeks to allow your gastrointestinal system to adjust. This dose typically produces mild appetite suppression with minimal side effects.

5.0 mg (50 units) is the first escalation step. Many patients experience noticeable appetite reduction and early weight loss at this level. It is also a common long-term maintenance dose for patients who tolerate it well and achieve steady results.

7.5 mg (75 units) is the intermediate dose. Some providers use it as a stepping stone between 5 mg and 10 mg to smooth the escalation for patients who experience side effects at larger dose jumps.

10.0 mg (100 units) is a full 1.0 mL syringe at this concentration. This is a high-efficacy maintenance dose. In the SURMOUNT trials, the 10 mg group achieved substantial weight loss. Note that drawing exactly 100 units requires filling the syringe to its maximum capacity — leave no room for error when reading the syringe at this level.

The 10 mg/mL concentration is one of the most commonly dispensed for compounded tirzepatide because it covers the full initiation and early-to-mid escalation range in a single syringe draw. Doses from 2.5 mg to 10 mg translate to 25 to 100 units, which falls within the capacity of a standard 1.0 mL U-100 syringe.

The math is also intuitive. Multiplying the milligram dose by 10 gives you the unit count directly. This simplicity reduces calculation errors compared to concentrations like 30 mg/mL, where common doses produce non-round unit numbers.

However, 10 mg/mL becomes impractical once patients escalate beyond 10 mg. At 12.5 mg, the required 125 units exceeds the 100-unit syringe capacity. Patients who advance to 12.5 mg or 15 mg should transition to a 20 mg/mL or 30 mg/mL vial.

At 10 mg/mL, most tirzepatide doses require a relatively large syringe compared to semaglutide.

For the 2.5 mg starting dose (25 units), a 0.3 mL (30-unit) syringe works and provides the most precise reading.

For 5.0 mg (50 units), a 0.5 mL (50-unit) syringe is ideal since the dose exactly fills it.

For 7.5 mg (75 units) and 10.0 mg (100 units), a 1.0 mL (100-unit) syringe is required. No smaller syringe can hold these volumes.

As a general rule at 10 mg/mL: start with a 0.3 mL syringe during initiation, upgrade to 0.5 mL at 5 mg, and move to 1.0 mL at 7.5 mg and above.

If your provider escalates your dose above 10 mg, a 10 mg/mL vial will no longer work with a single syringe. At 12.5 mg, you would need 125 units — 25 more than a 1.0 mL syringe can hold. Splitting a dose across two syringes is not recommended.

Switching to a 20 mg/mL vial brings 12.5 mg down to 62.5 units and 15 mg down to 75 units, both within standard syringe capacity. A 30 mg/mL vial further reduces these to approximately 42 and 50 units respectively.

Always recalculate your unit count when your concentration changes. The milligram dose stays the same, but the number of units on your syringe will be different. Use the formula or a dosage calculator to verify before your first draw from a new-concentration vial.